Black Rock Inc. Metacrine, Inc. Transaction History

Black Rock Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.36 - $0.63 $14,193 - $24,839	-39,427 Reduced 28.19%	100,444 $51,000
Q1 2022 May 12, 2022	SELL	$0.43 - $0.7 $828 - $1,348	-1,926 Reduced 1.36%	139,871 $85,000
Q4 2021 Feb 10, 2022	BUY	$0.64 - $3.83 $2,481 - $14,852	3,878 Added 2.81%	141,797 $95,000
Q3 2021 Nov 09, 2021	BUY	$2.61 - $3.84 $59,494 - $87,532	22,795 Added 19.8%	137,919 $473,000
Q2 2021 Aug 11, 2021	BUY	$3.37 - $5.73 $387,967 - $659,660	115,124 New	115,124 $438,000

Ticker MTCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,569,500
Description
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.